Press Releases
November 2009 - HUYA BIOSCIENCE INTERNATIONAL ESTABLISHES STRATEGIC PARTNERSHIP WITH SCHOOL OF MEDICINE AND PHARMACY, OCEAN UNIVERSITY OF CHINA
San Diego, CA – November 8, 2009 - HUYA Bioscience International, a leader in globalizing China’s biopharmaceutical innovation, today announced a strategic partnership with the School of Medicine and Pharmacy, Ocean University of China. The agreement is another in a series of collaborations that HUYA has established with China’s leading research and development institutions to enable and accelerate the global development and commercialization of novel biopharmaceutical product opportunities originating in China.
Read Full Press Release
May 2009 - SOLVAY PHARMACEUTICALS ANNOUNCES STRATEGIC PARTNERSHIP WITH HUYA TO ACCESS NEW DRUG CANDIDATES FROM CHINA
Brussels, 18 May 2009 - Solvay Pharmaceuticals announces it has signed an agreement with HUYA Bioscience International, a company specialized in enabling and accelerating global codevelopment of novel biopharmaceutical product opportunities originating in China.
Read Full Press Release
21 April 2009 - HUYA BIOSCIENCE ANNOUNCES STRATEGIC ALLIANCE WITH ABBOTT ON DRUG AND BIOMARKER DEVELOPMENT CANDIDATES FROM CHINA
Collaboration will leverage HUYA's growing Chinese bioscience network
San Diego, CA, April 21, 2009 – HUYA Bioscience International, a leader in US/China pharmaceutical co-development, today announced an agreement with Abbott to identify and pursue proprietary preclinical and clinical drug candidates that originate in China.
Read Full Press Release
18 February 2009 - HUYA BIOSCIENCE INT’L ANNOUNCES COLLABORATION AGREEMENT WITH THE BEIJING INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES AND PEKING UNION MEDICAL COLLEGE
San Diego, February 18 2009 - HUYA Bioscience International, the leader in US/China pharmaceutical co-development, today announced a partnership agreement with the Beijing Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College (collectively – The Beijing Institute of Materia Medica, BIMM).
Read Full Press Release
15 December 2008 - HUYA BIOSCIENCE ANNOUNCES AGREEMENT TO PROVIDE SCHERING- PLOUGH WITH DRUG DEVELOPMENT CANDIDATES FROM CHINA
Schering-Plough has selected HUYA to identify and present to Schering-Plough on an exclusive basis proprietary lead, preclinical and clinical drug candidates in specific therapeutic areas that originate in China.
Read Full Press Release
14 April 2008 - HUYA BIOSCIENCE INT’L ANNOUNCES FIRST PRE-IND OUTCOME FOR A DEVELOPMENT STAGE COMPOUND SOURCED FROM CHINA – HBI-8000, PROMISING NEW CANCER COMPOUND
FDA feedback validates HUYA’s Integrated Co-Development Model for China-sourced Drug Candidates
Read Full Press Release
3 March 2008 - HUYA BIOSCIENCE INT’L ANNOUNCES WORLD-CLASS CLINICAL ADVISORY TEAM FOR NEW ANTI-ARRHYTHMIC COMPOUND SOURCED FROM CHINA
Team includes Peter Kowey, pioneer of anti-arrhythmic drugs/devices in U.S., and Eric Topol, one of top 10 cited biomedical researchers over past decade
Read Full Press Release
3 March 2008 - HUYA BIOSCIENCE INT’L ANNOUNCES CLINICAL TRIAL MILESTONES IN CHINA FOR PROMISING NEW ANTI-ARRHYTHMIC COMPOUND; DATA SUPPORTS DESIRABLE SAFETY PROFILE
Progress validates HUYA’s innovative U.S./China pharmaceutical co-development model
Read Full Press Release
2 October 2007 - HUYA BIOSCIENCE INTERNATIONAL LICENSES CLINICAL STAGE ANTI-ARRHYTHMIC COMPOUND FROM THE SHANGHAI INSTITUTE OF MATERIA MEDICA
HUYA Bioscience International (HUYA), a rapidly expanding biopharmaceutical company focused on the development of key disease-fighting drugs sourced from China, announced today that it has licensed a novel clinical stage anti-arrhythmic compound from the prestigious Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences.
Read Full Press Release
24 May 2007 - HUYA BIOSCIENCE INTERNATIONAL AND CHIPSCREEN BIOSCIENCES INITIATE A PHASE I CLINICAL CANCER TRIAL
HUYA Bioscience International, LLC and Chipscreen Biosciences Ltd. announced today that a Phase I clinical trial has been initiated in China with the compound Chidamide (CS055) /HBI-8000, an investigational cancer compound. HUYA holds exclusive rights to the compound (HBI-8000) worldwide outside of China, while Chipscreen maintains rights in China. The Phase I clinical trial is designed to assess the safety, tolerability and pharmacokinetics of the compound.
Read Full Press Release
6 March 2007 - HUYA BIOSCIENCE LICENSES CHIDAMIDE CANCER COMPOUND FROM CHIPSCREEN BIOSCIENCES
HUYA Bioscience International, LLC, announced today that it has exclusively licensed worldwide rights outside China to the cancer compound chidamide from Shenzhen Chipscreen Biosciences Ltd. Chidamide, is an investigational cancer compound currently approved to initiate a Phase I clinical trial in China.
Read Full Press Release
9 January 2007 - ORGANON PARTNERS WITH HUYA TO IDENTIFY AND DEVELOP CHINESE BIOPHARMACEUTICALS COLLABORATION LOOKS FOR OPPORTUNITIES TO EXPAND THE ORGANON BIOTECH RESEARCH PROGRAMS AND FACILITATE LINKS WITH CHINA'S BIOTECH INDUSTRY
HUYA Bioscience International, LLC, announced today that it has exclusively licensed worldwide rights outside China to the cancer compound chidamide from Shenzhen Chipscreen Biosciences Ltd. Chidamide, is an investigational cancer compound currently approved to initiate a Phase I clinical trial in China.
Read Full Press Release